Rheumatology
News
FDA advisory panel unanimously backs biosimilars for Humira, Enbrel
News
FDA’s arthritis advisory committee unanimously backs biosimilar Humira
Conference Coverage
Etanercept biosimilar proves effective, tolerated in phase III trial
Key clinical point: Biosimilar etanercept (CHS-0214) was shown to be as effective and well tolerated as etanercept. Major finding: ACR 20 at 24...
Conference Coverage
JAK-1 inhibitors heading for validation in phase III trials
Key clinical point: Two new oral Janus kinase inhibitors selective for JAK-1 have shown promising efficacy and safety in separate phase II trials...
Conference Coverage
New fragility fracture recommendations emphasize coordination of care
Conference Coverage
HCQ eye toxicity needs experience to assess
Key clinical point: Several eye abnormalities can be mistaken for hydroxychloroquine-related eye toxicity, making specialist ophthalmic assessment...
Commentary
Pharma jousts statistically for an ankylosing spondylitis edge
News
Immunosuppressive regimens did not affect risk of cancer recurrence in meta-analysis
Among patients with immune-mediated diseases and a history of malignancy, cancer recurrence rates were similar regardless of whether they received...
Conference Coverage
NSAID plus TNFi linked to less ankylosing spondylitis progression
Key clinical point: Ankylosing spondylitis patients treated with a TNF inhibitor plus an NSAID had the lowest level of new bone formation during...
Conference Coverage
NSAID plus TNFi linked to less ankylosing spondylitis progression
Key clinical point: Ankylosing spondylitis patients treated with a TNF inhibitor plus an NSAID had the lowest level of new bone formation during...
News
Actemra may reduce scleroderma skin thickening
The interleukin-6 inhibitor tocilizumab (Actemra) substantially reduced skin thickening in patients with systemic sclerosis in the “proof-of...